 |
 |

Arthritis Medications and Cardiovascular Events
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
To the Editor: The US Food and Drug Administration recently announced the premature discontinuation of ADAPT due to an apparent increase in adverse cardiovascular events associated with naproxen.1 Because previous reports have shown naproxen to have a cardioprotective effect, this finding was unexpected and has caused a considerable amount of confusion among practitioners and the public.2
ADAPT and other similar trials evaluating the effect of long term exposure to NSAIDs allow patients to continue receiving cardioprotective doses of aspirin (<325 mg/d) without controlling for allocation between arms, timing of aspirin administration in relationship to the NSAID dose, or dosage form of aspirin used (soluble vs enteric coated).3 Catella-Lawson et al4 observed that administration of ibuprofen (a propionic acid derivative similar to naproxen) with or prior to aspirin negates the antiplatelet effect of aspirin by binding to a serine residue in the channel that aspirin must traverse before it can access . . . [Full Text of this Article]
David F. Lehmann, MD, PharmD
lehmannd@upstate.edu State University of New York Upstate Medical University Syracuse
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
RELATED ARTICLES
Arthritis Medications and Cardiovascular Events
Mario Guslandi
JAMA. 2005;293(16):1975-1976.
EXTRACT
| FULL TEXT
Arthritis Medications and Cardiovascular Events
Simeon Pollack
JAMA. 2005;293(16):1976.
EXTRACT
| FULL TEXT
Arthritis Medications and Cardiovascular EventsReply
Eric J. Topol
JAMA. 2005;293(16):1976-1977.
EXTRACT
| FULL TEXT
Arthritis Medicines and Cardiovascular Events"House of Coxibs"
Eric J. Topol
JAMA. 2005;293(3):366-368.
EXTRACT
| FULL TEXT
|